| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3b topline data readout example | NurOwn ALS | Phase 3b | — | Cell Therapies | - | ||
Phase 3b topline data readout example | NurOwn ALS | Phase 3b | — | Cell Therapies | - | ||
Phase 3b topline data readout example | NurOwn ALS | Phase 3b | — | Cell Therapies | - |
Recent Updates
Recently added Catalysts
Brainstorm Cell Therapeutics Inc.$0.68
-0.02 (-3.53%)
D 20Pipeline Score Richly Valued Biotech · Clinical
Market Cap
11.51 M
EPS
-1.98
P/E Ratio
-
Value Trade
1.27 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
762.00 K
Operating CF
-1.32 M
Total Assets
755.00 K
Total Liabilities
11.76 M
Equity
-11.01 M
D/E Ratio
12,345
-6.77 %
Week
-6.4 %
1 Month
44.44 %
3 Month
-40.91 %
6 Month
-99.44 %
5 Year
-75.52 %
All Time
Cash Data
Cash Position
206.00 K
Monthly Burn
440.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
1.82 K
52 Week Range
0.72 - 6
% held by Insiders
22.32 %
% held by Institutions
10.4 %
Enterprise Value
11.64 M
Total Shares
9.84 M
Short %
6.06 %
Float Shares
7.64 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D20
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 18%
Micro Cap (rank 743 of 905)
Percentile RankBrainstorm Cell Therapeutics Inc. faces pipeline headwinds (20/100), with $749M risk-adjusted pipeline value, led by NurOwn in Multiple Sclerosis, Chronic Progressive (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NurOwn Monoclonal antibody | Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | NCT03280056 | 51% | $704M | COMPLETED | 196 | - | - | Sep 29, 2020 | - | Feb 29, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NurOwn | amyotrophic lateral sclerosis (ALS) | Phase 3 | 2025-06-16 | |||
NurOwn | amyotrophic lateral sclerosis (ALS) | Phase 3 | 2025-06-16 | |||
NurOwn | amyotrophic lateral sclerosis (ALS) | Phase 3 | 2025-06-16 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BCLI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Brainstorm Cell Therapeutics Inc. (BCLI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BCLI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BCLI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BCLI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BCLI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BCLI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How BCLI ranks across every disease it competes inCompetitive Position is a premium feature
See how BCLI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial